Managing Adverse Events With Immune Checkpoint Agents.

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Immune checkpoint inhibitors (ICIs), including anti-cytotoxic T-lymphocyte antigen 4 and anti-programmed cell death 1/programmed cell death 1 ligand antibodies, demonstrate significant clinical efficacy across various cancers.
• Despite their success, ICIs are associated with immune-related adverse events (irAEs), which can be severe and potentially life-threatening.
• Effective management of irAEs is crucial for optimizing patient treatment outcomes and tolerability.

Purpose of the Study:

• To describe the most common immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapy.
• To provide a structured approach for the clinical management of specific irAEs.
• To highlight the importance of early identification, risk assessment, and prompt treatment of irAEs.

Main Methods:

• This review synthesizes current literature on immune checkpoint inhibitors and their associated adverse events.
• It focuses on describing the clinical presentation and incidence of common irAEs.
• Evidence-based recommendations for the management of irAEs are presented.

Main Results:

• Immune checkpoint inhibitors elicit a distinct spectrum of irAEs affecting various organ systems.
• Common irAEs include dermatitis, colitis, hepatitis, and endocrinopathies.
• The severity of irAEs ranges from mild to life-threatening, necessitating vigilant monitoring.

Conclusions:

• Immune checkpoint inhibitors are effective cancer therapeutics, but careful management of irAEs is essential.
• Early recognition and appropriate treatment of irAEs can mitigate toxicity and improve patient outcomes.
• A proactive approach involving patient-provider communication and risk stratification is key to successful ICI therapy.